OTCMKTS:CSLLY

CSL Stock Forecast, Price & News

$112.34
-0.19 (-0.17 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$111.88
$113.96
50-Day Range
$101.72
$114.56
52-Week Range
$94.05
$117.98
Volume29,145 shs
Average Volume47,339 shs
Market Capitalization$102.38 billion
P/E Ratio43.04
Dividend Yield0.96%
Beta0.58
30 days | 90 days | 365 days | Advanced Chart
Receive CSLLY News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.


CSL logo

About CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CSL (OTCMKTS:CSLLY) Frequently Asked Questions

Is CSL a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CSL stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CSLLY, but not buy additional shares or sell existing shares.
View analyst ratings for CSL
or view top-rated stocks.

What stocks does MarketBeat like better than CSL?

Wall Street analysts have given CSL a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CSL wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CSL?

CSL saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 8,400 shares, a decrease of 80.4% from the August 15th total of 42,900 shares. Based on an average daily trading volume, of 74,200 shares, the days-to-cover ratio is currently 0.1 days.
View CSL's Short Interest
.

How has CSL's stock price been impacted by Coronavirus (COVID-19)?

CSL's stock was trading at $101.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CSLLY shares have increased by 11.1% and is now trading at $112.34.
View which stocks have been most impacted by COVID-19
.

How often does CSL pay dividends? What is the dividend yield for CSL?

CSL declared a Semi-Annual dividend on Thursday, February 18th. Stockholders of record on Thursday, March 4th will be given a dividend of $0.47 per share on Monday, April 12th. The ex-dividend date is Wednesday, March 3rd. This is an increase from CSL's previous Semi-Annual dividend of $0.45.
View CSL's dividend history
.

Is CSL a good dividend stock?

CSL pays an annual dividend of $1.08 per share and currently has a dividend yield of 0.96%. The dividend payout ratio of CSL is 41.38%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CSL will have a dividend payout ratio of 36.99% next year. This indicates that CSL will be able to sustain or increase its dividend.
View CSL's dividend history.

Who are CSL's key executives?

CSL's management team includes the following people:
  • Paul Roger Perreault, Chief Executive Officer, Executive Director & MD
  • Paul McKenzie, Chief Operating Officer
  • Joy Carolyn Linton, Chief Financial Officer
  • Andrew Cuthbertson, Chief Scientific Officer & Executive Director
  • William Mezzanotte, Chief Medical Officer, EVP & Head-R&D

Who are some of CSL's key competitors?

What is CSL's stock symbol?

CSL trades on the OTCMKTS under the ticker symbol "CSLLY."

How do I buy shares of CSL?

Shares of CSLLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CSL's stock price today?

One share of CSLLY stock can currently be purchased for approximately $112.34.

How much money does CSL make?

CSL has a market capitalization of $102.38 billion and generates $10.31 billion in revenue each year. The company earns $2.38 billion in net income (profit) each year or $2.61 on an earnings per share basis.

How many employees does CSL have?

CSL employs 25,000 workers across the globe.

When was CSL founded?

CSL was founded in 1904.

What is CSL's official website?

The official website for CSL is www.csl.com.au.

Where are CSL's headquarters?

CSL is headquartered at 45 Poplar Road, Parkville C3, 3052.

How can I contact CSL?

CSL's mailing address is 45 Poplar Road, Parkville C3, 3052. The company can be reached via phone at (139) 389-1911 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.